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Abstract The replacement of either Tyr-181 or Tyr-188 of 
human immunodeficiency virus type 1 (HIV-1) reverse transcrip- 
tase (RT) by the corresponding HIV-2 RT amino acids lie-181 
or Leu-188 is known to result in active mutant enzymes (YI81I; 
Y188L) with virtual loss of sensitivity towards three structural 
classes of nonnucleoside RT inhibitors; L-697,661, nevirapine, 
and TIBO R82913. The bisheteroarylpiperazine (BHAP) U- 
90152S, a highly specific inhibitor (ICso, 0.29 + 0.01 /zM) of 
HIV-I RT, inhibited the recombinant YI81I and YI88L HIV-1 
RT mutants with ICso values of 3.6 + 0.15/zM and 0.71 + 0.02 
/xM, respectively. Construction and in vitro analysis of double 
mutants Y1811/Y188L and Y181C/Y188L of HIV-1 RT showed 
> 150-fold resistance to U-90152S. An HIV-2 RT mutant con- 
taining amino acids 176-190 from HIV-1 RT acquired full sensi- 
tivity to U-90152S (ICso, 0.26 + 0.01/tM). It is concluded that 
simultaneous mutations at Tyr-181 and Tyr-188 of HIV-1 RT 
promotes resistance to U-90152S. 
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1. Introduction 
The human immunodeficiency virus type 1 (HIV-1) reverse 
transcriptase (RT) is a well established target for therapeutic 
intervention of AIDS [1]. A number of different classes of 
highly specific nonnucleoside inhibitors of the HIV-1 RT have 
been recently described [2-7]. The most widely studied classes 
include the pyridinone L-697,661 [2], nevirapine [3,4], TIBO 
R82913 [5] and the BHAPs [6,7]. However, potential usefulness 
of some of these compounds i confounded by the accumula- 
tion of resistant viral variants both in cell culture as well as in 
HIV-1 infected patients [8-15]. 
A three-dimensional co-crystal-structure of HIV-1 RT and 
nevirapine shows that the side chains of Tyr-181 and Tyr-188 
are in contact with nevirapine [16]. The structural data are 
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consistent with the previous chemical cross-linking studies im- 
plicating the involvement of these residues in drug binding 
[17-19]. The replacement of Tyr- 181 or Tyr- 188 with the corre- 
sponding HIV-2 RT amino acids (Ile-181 or Leu-188) resulted 
in HIV-1 RT mutants which were insensitive to L-697,661, 
nevirapine, and TIBO 82913 [20]. It is believed that insensitivity 
of HIV-2 RT to these NNRTIs is primarily due to the presence 
of Ile-181 or Leu-188 [17,20-22]. Subsequently, there were dif- 
ferences in the pattern of resistance mutations observed in the 
presence of NNRTIs [11,23-27]. Taken together, these studies 
suggest that there is a common binding pocket [16] and overlap- 
ping binding sites for different inhibitors. 
In contrast to other classes of NNRTIs, the BHAP U-90152S 
selects for a resistance mutation (P236L) at a conserved site of 
RT with the consequence of conferring sensitization to other 
NNRTIs [11]. Recent site-directed mutagenesis studies at and 
around P236 have suggested that the P236L mutation triggers 
both resistance toU-90152S and sensitization to L-697,661 [28]. 
In this paper we investigate activity of U-90152S against he 
mutant HIV-1 RT enzymes bearing mutations at Tyr-181, Tyr- 
188, or Tyr-181/Tyr-188. Our studies show that U-90152S is 
active against the mutant RT enzyme YI81I or Y188L. Studies 
with the double mutants uggest a requirement for simultane- 
ous mutations in HIV-1 RT at Y181 and Y188 for HIV-1 to 
escape U-90152S-mediated inhibition. Furthermore, we dem- 
onstrate that the U-90152S-binding requires the 176-190 do- 
main from the fl strands 9 and 10 of HIV-1 RT. 
2. Materials and methods 
2.1. HIV-1 RT inhibitors and other chemicals 
L-697,661 and U-90152S were kindly supplied by Drs. H.W. Smith 
and D.L. Romero f Upjohn Laboratories. General laboratory chemi- 
cals were purchased from Sigma and Bio-Rad. Low melting point 
agarose, Taq polymerase, T4 ligase, restriction enzymes EcoRI and 
HindlII, and molecular weight markers were from Gibco/BRL. The 
substrates poly(rA) :oligo(dT), poly(rC) : oligo(dG), deoxythymidine 
triphosphate, deoxyguanosine triphosphate, and Chelating Sepharose 
for IMAC were purchased from Pharmacia/LKB iotechnology Inc. 
The [3H]dTTP and [3H]dGTP were obtained from DuPont NEN and 
diluted with cold dTTP and dGTP, respectively. 
2.2. Site-directed mutagenesis and expression of HIV-1 RT mutants 
The hexa-His tagged HIV-1 RT expression plasmid called DE-5,2 
[29] was used to generate site-specific point mutations by the 'mega- 
primer' method [30], as described elsewhere [28]. For each RT mutant, 
the 1.7 kb RT gene fragment obtained was subcloned into the expres- 
sion vector pKK223-3 that had been digested with EcoRI and HindlII 
at he multiple cloning site [29]. Competent E. coli strain JM 109 was 
transformed with the mutated RT construct and resulting colonies were 
screened for expression of the p66 HIV-1 RT protein upon induction 
with 1 mM IPTG [29]. The E. coli cells were pelleted, lysed by SDS, and 
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the cell lysate was analyzed by 12% SDS-PAGE [31]. The mutated 
region of the selected clones was then sequenced by the dideoxy method 
using Sequenase Version 2.0 sequencing kit and 35S. 
2.3. Cloning and expression of HIV-2 RT containing the amino acid 
sequence 176-190 (PDIVIYQYMDDLYVG) from HIV-1 RT 
Chimeric HIV-2 RT substituted with amino acids at position 176 to 
190 from HIV-1 RT was constructed from plasmid NSF-20B-5. A hexa 
histidine linker was engineered into the N-terminal of HIV-2 RT (cod- 
ing region 2381-4078, HIV-2rod isolate, GenBank accession No. 
M15390) to facilitate purification by IMAC [28]. Cloning and expres- 
sion of the chimeric HIV-2 RT protein was performed as described 
above. 
2.4. Purification and characterization fHIV-1 RTmutants 
The IMAC purification of the desired mutants, including the HIV-2 
RT mutant, containing the hexa-histidine tag was carried out essentially 
as detailed elsewhere [32]. The p661p51 heterodimers of the double 
mutants were obtained by in vitro processing of the corresponding p66 
HIV-1 RT mutants with HIV-1 protease as described for the wild type 
p66 HIV-1 RT [32]. 
2.5. RNA-dependent DNA polymerase RT activity assay 
Reverse transcriptase activity of HIV-1 RT and its mutants was 
determined using the previously described assay using poly(rA): 
oligo(dT) as the template primer [28,32]. Protein concentration was 
determined by the Bradford protein assay using BSA as the standard 
protein [32]. 
2.6. IGo determinations 
For inhibition studies, enzymatic assays were carried out in the pres- 
ence and absence of HIV-I RT inhibitors. All the inhibitors were pre- 
pared in 50% DMSO as 25× stock solutions and 2 pl of each inhibitor 
was added to give the desired inhibitor concentration. For determina- 
tion of relative ICs0 values with standard eviations, tatistical nalysis 
of the upper and lower confidence limits were calculated using the 3 
parameter logistic model [33]. 
2.7. Kinetic studies 
Kinetic studies were performed with varying template-primer 
[poly(rA) : oligo(dT)] concentrations from 0.075 pM to 7.5 pM [32]. The 
rate of incorporation of [3H] nucleotides by wild type and mutant 
enzymes (2 nM) was linear for 30 min. Studies were done under steady 
state conditions in 10 minassays as described above. The kinetic param- 
eter Km q~M) and the catalytic onstant kca~ (nmol [3H]dTTP incorpo- 
rated/h) were determined using the non-linear regression analysis soft- 
ware program (Enzfitter; Biosoft), based on the Michaelis-Menten 
equation. 
3. Results and discussion 
3.1. Studies with HIV-1 RT  mutants Y181I and Y188L 
Significant homologies between HIV-1 RT and HIV-2 RT 
Table 1 
Fifty percent inhibition of RNA-dependent DNA polymerase activity 
of mutant enzymes of HIV-1 RT by U-90152S and L-697,661 
HIV-1 RT ICs0 (tiM)" 
U-90152S L-697,661 
Wild type 0.29 + 0.01 (1.0) 0.23 + 0.01 (1.0) 
Y181I 3.60 + 0.15 (12.4) > 100 (>400) 
Y188L 0.71 + 0.02 (2.4) 35.2 + 1.50 (153) 
V106I 0.30 + 0.0l (1.0) 0.21 + 0.0l (1.0) 
aThe RT activity assays were carried out in the presence of 
poly(rA):oligo(dT) as the template primer. IC50 values greater 
than 100/IM cannot be determined accurately due to solubility limits. 
The data represent mean + S.D. (n = 3). The fold differences in IC50 
were calculated relative to the wild type HIV-1 RT and are shown in 
parenthesis. 
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Fig. 1. Chemical structures of the BHAP U-90152S (a) and L-697,661 
(b). These structures were published in the following references: 
L-697,661 in [20]; U-90152S in [7]. 
have been noted from an alignment of sequences in the fl 
strands 5, 6, 9, 10, 12, 13, and 14 [17-21,28]. These ]~ strands 
are important because they form the inhibitor binding pocket 
and are close to the polymerase active site [16,34-36]. We con- 
structed a number of HIV-1 RT single and double mutants 
containing corresponding substitutions from HIV-2 RT. All the 
HIV-1 RT mutants were purified as p66 homodimers from 
crude E. coli extracts in the same manner by IMAC, as de- 
scribed previously for the wild type RT [28,32]. The chemical 
structures of the compounds used in the inhibition studies of 
these HIV-1 RT mutants are depicted in Fig. 1. 
The RNA-dependent DNA polymerase activity of the HIV-1 
RT single mutants was determined in the presence of U-90152S 
and the pyridinone derivative L-697,661 (Table 1). As shown, 
U-90152S and L-697,661 are potent inhibitors of the wild type 
enzyme with ICs0 values of 0.29 + 0.01 pM and 0.23 + 0.01 pM,  
respectively. The single mutants Y181I and Y188L were highly 
resistant towards L-697,661, in agreement with an earlier eport 
[20]. However, these HIV-1 RT mutants were inhibited by U- 
90152S with IC~0 values of 3.60 + 0.15pM and 0.71 + 0.02pM, 
respectively. Similar results were obtained when poly(rC): 
oligo(dG) was the template-primer (data not shown). The 
V106I HIV-1 RT mutant, containing the corresponding HIV-2 
RT amino acid from the fl strand 6, was also included in the 
study. Both these compounds inhibited the single mutant V 106I 
(Table 1), suggesting that V106 is not critical for inhibitory 
activity of U-90152S or L-697,661. 
Fig. 2 shows U-90152S-mediated inhibition profiles of HIV-1 
RT mutants bearing substitutions from HIV-2 RT. For com- 
parison purposes, U-90152S results with a HIV-1 RT mutant 
containing triple substitutions (H235W/D237T/T240K) from 
HIV-2 RT [28] are also presented. Fig. 2 also shows the effect 
of L-697,661 on the Y181I and Y188L HIV-1 RT mutants. In 
contrast o the three well known classes of NNRTIs  [20], U- 
90152S is still relatively active versus the HIV-1 RT single 
mutants Y181I and Y188L. Our results suggest that these tyro- 
sines alone interact very weakly with U-90152S. 
3.2. Studies with the double mutants o f  HIV-1 RT  
The above conclusions led to the view that perhaps simulta- 
neous presence of two or more mutations at the non-conserved 
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sites in the fl strands 9 and 10 might be required to produce 
HIV-1 RT that is highly resistant to U-90152S. Therefore, two 
double mutants were cloned, expressed, and purified. The dou- 
ble mutant Y 181 I/Y 188L carried amino acid substitutions from 
HIV-2 RT and had been reported by others [18,19,27]. The 
other double mutant Y181C/Y188L has not been reported and 
contains amino acid substitutions based on the presence of 
~ndividual mutations Y181C [12] or Y188L [14] in resistant viral 
solates from patients treated with NNRTIs. The relative spe- 
.-ific RT activities were 60990 + 1252 units/mg and 53518 + 924 
anits/mg for the Y181I/Y188L and Y181C/Y188L mutants, 
respectively. This was similar to specific RT activity of 
-~8916 + 633 units/mg for the wild type HIV-1 RT. The ratio of 
the kinetic parameters, kc~t and Km, for the double mutants was 
also indistinguishable from the wild type HIV-I RT (data not 
~hown). 
As shown in Table 2, the double mutants Y181I/Y188L and 
Y181C/Y188L showed >150-fold resistance to U-90152S, irre- 
spective of the nature of the template primer used in the assay. 
Notably, these results were indistinguishable when compared 
with the results of the corresponding p66/p51 heterodimers of
the double mutants (data not shown). A side by side compari- 
son of the Y181I/Y188L mutant profile with the Y181I and 
Y188L single mutants is shown in Fig. 2. It is concluded that 
the simultaneous presence of both the mutations, which alone 
were inadequate to produce resistant enzymes (Fig. 2), resulted 
in a highly insensitive HIV-1 RT. Since both mutations in the 
Y181I/Y188L double mutant are derived from HIV-2 RT, it is 
likely that insensitivity of HIV-2 RT towards U-90152S, to 
some extent, is related to the simultaneous absence of tyrosines 
at 181 and 188 in this enzyme. 
3.3. Studies with mutant HIV-2 RT  containing the 17~190 
amino acids f rom HIV-1 RT  
It has been reported that an HIV-2 RT mutant with amino 
acid substitutions 176-190 from HIV-1 RT, called RT-2 (176- 
190), acquires sensitivity to nevirapine and TIBO R82913 
[18,19]. We also constructed an HIV-2 RT substituted with the 
corresponding amino acids 176-190 (PDIVIYQYMDDLYV- 
G) from HIV-1 RT and showed that its U-90152S-sensitivity 
was indistinguishable from the wild type HIV-1 RT (Table 2). 
We conclude that the 176 190 domain in HIV-1 RT is involved 
in U-90152S binding. These results are consistent with our 
recent studies [28] which suggest hat the P236L-mediated sen- 
sitization to L-697,661 and resistance to U-90152S are the con- 
Table 2 
Sensitivity of multiple mutants of HIV-1 RT and HIV-2 RT towards 
U-90152S 
Enzyme U-90152S Inhibition (IC5o, pM) a 
rA : dT rC : dG 
Wild type HIV-1 RT 0.29 + 0.01 (1.0) 0.12 + 0.003 (1.0) 
Y181I/Y188L HIV-1 RT 62 + 2.50 (213) 26.3 + 0.88 (219) 
Y181C/Y188L HIV-I RT > 100 (>300) > 100 (>300) 
Wild type HIV-2 RT > 100 (>300) > 100 (>300) 
HIV-2 RT (176-190) 0.27 + 0.01 (1.0) 0.12 _+ 0.004 (1.0) 
~Fifty percent inhibition of RNA-dependent DNA polymerase activity 
was determined ither using poly(rA): oligo(dT) or poly(rC): oligo(dG) 
as the template primer. ICs0 values greater than 100 pM cannot be 
determined accurately due to solubility limits. The data represent 
mean + S.D. (n = 3). The fold differences in ICs0 were calculated rela- 
tive to the wild type HIV-1 RT and are shown in parenthesis. 
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Fig. 2. Relative resistance of HIV-1 RT mutants and the wild type 
HIV-2 RT to U-90152S. Data for the H235W, D237T and T240K 
mutants are based on the results from [28]. Relative resistance was 
calculated as fold-increase in IC50, by dividing the IC50 for each mutant 
with the ICs0 for the wild type HIV-1 RT enzyme. The data are pre- 
sented relative to the wild type HIV-1 RT, which is arbitrarily assigned 
a value of 1. For comparison purposes, resistance profiles of Y 1811 and 
Y188L HIV-1 RT mutants in the presence of L-697,661 are also in- 
cluded. The variation in the triplicate xperiments was -<5%. For other 
details, see section 2. 
sequence of alterations in the geometry of the inhibitor binding 
pocket [16,35]. 
In addition to the well known Y181C and Y 188L mutations, 
the Y181I mutation has also been observed in cell culture ex- 
periments [37]. The unique activity of U-90152S versus the 
Y181I or Y188L HIV-1 RT mutant (Fig. 2) distinguishes it
from the other well known classes of NNRTIs [20-22,26]. The 
BHAP U-90152S is also active versus the Y181C HIV-1 RT 
mutant and selects for a P236L resistance mutation in cell 
culture experiments [25]. These characteristics of U-90152S are 
not shared by TIBO R82913, nevirapine, and L-697,661. How- 
ever, the U-90152S-binding domain in HIV-1 RT seems to be 
also localized to residues 176-190 from fl strands 9 and 10. 
Thus, it is tempting to speculate that U-90152S is targeted 
directly to the conserved amino acids of these fl strands such 
that viral variants containing substitutions at these sites are 
incompatible with viral replication. Consequently, in the pres- 
ence of U-90152S HIV-1 is forced to select for a resistant 
mutation (P236L) at the fll 3-fl14 reverse turn [36], a site which 
does not appear to be in direct contact with the inhibitor [28]. 
The observed high level resistance (> 150-fold) of the double 
mutants (Y181]/Y188L and Y181C/Y188L) toward U-90152S 
seems to be the consequence of changes in the shape of the 
inhibitor binding pocket [16]. The loss of inhibitory activity of 
U-90152S versus the double mutant Y 181 I/Y 188 L also implies 
that the simultaneous presence of both Ile 181 and Leu 188 in 
HIV-2 RT may play a role in its resistance to U-90152S. These 
results are consistent with the observation that sensitivity to 
U-90152S can be conferred onto HIV-2 RT by substitution of 
residues 176-190 from HIV-1 RT (Table 2). 
It is becoming apparent that viral resistance during monoth- 
erapy with RT inhibitors is a serious concern. Thus, there is an 
urgent need for potent antiHIV agents for evaluation i  combi- 
nation with other active anti-HIV compounds. The chances of 
success of such an approach should increase if the compounds 
act on the same target with different mechanisms. Accordingly, 
in combination therapy, there is also the potential to derive 
mutually counteracting resistance mutations. 
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